CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus

Clinical and Experimental Immunology

Volumn 145, Issue 2, 2006, Pages 235-242

  Patschan, S ^a   Dolff, S ^a   Kribben, A ^a   Durig J ^a   Patschan, D ^a   Wilde, B ^a   Specker, C ^b   Philipp, T ^a   Witzke, O ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Eye Hospital   (Germany)

Author keywords

CD134; Costimulation; Lupus nephritis; Systemic lupus erythematosus; T cell

Indexed keywords

ANTIGEN; AUTOANTIBODY; B7 ANTIGEN; CD134 ANTIGEN; CD137 ANTIGEN; CD137 LIGAND; CD40 LIGAND; CD45RO ANTIGEN; CD70 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTICAL PARAMETERS; ANTIBODY PRODUCTION; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BIOPSY; BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; FREQUENCY ANALYSIS; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION;

ACUTE DISEASE; ADULT; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, CD80; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE SUBSETS; MALE; MEMBRANE GLYCOPROTEINS; MICROSCOPY, CONFOCAL; MIDDLE AGED; NEPHRITIS; OX40 LIGAND; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; STATISTICS, NONPARAMETRIC; SUBSTANCE-RELATED DISORDERS; TUMOR NECROSIS FACTORS;

EID: 33745937715     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03141.x     Document Type: Article

References (20)

1. Watts TH, DeBenedette MA. T cell co-stimulatory molecules other than CD28. Curr Opin Immunol 1999; 11:286-93.
2. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors, co-stimulation from CD28, inducible co-stimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 2004; 172:104-13.
3. Foell J, Strahotin S, O'Neil SP et al. CD137 co-stimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest 2003; 111:1505-18.
4. Liang B, Kashgarian MI, Sharpe AH et al. Autoantibody responses and pathology regulated by B7-1 and B7-2 co-stimulation in MRL/ lpr lupus. J Immunol 2000; 165:3436-43.
5. Kinoshita K, Tesch G, Schwarting A et al. Costimulation by B7-1 and B7-2 is required for autoimmune disease in MRL-Faslpr mice. J Immunol 2000; 164:6046-56.
6. Daikh DI, Finck BK, Linsley PS et al. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 co-stimulation pathways. J Immunol 1997; 159:3104-8.
7. Bijl M, Horst G, Limburg PC et al. Expression of co-stimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis 2001; 60:523-6.
8. Abe K, Takasaki Y, Ushiyama C et al. Expression of CD80 and CD86 on peripheral blood T lymphocytes in patients with systemic lupus erythematosus. J Clin Immunol 1999; 19:58-66.
9. Aten I, Roos A, Claessen N et al. Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol 2000; 11:1426-38.
10. Kalunian KC, Davis JC Jr, Merrill JT et al. Treatment of systemic lupus erythematosus by inhibition of T cell co-stimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:3251-8.
11. Boumpas DT, Furie R, Manzi S et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48:719-27.
12. Grassme H, Jendrossek V, Riehle A et al. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med 2003; 9:322-30.
13. Imura A, Hori T, Imada K et al. OX40 expressed on fresh leukemic cells from adult T-cell leukemia patients mediates cell adhesion to vascular endothelial cells: implication for the possible involvement of OX40 in leukemic cell infiltration. Blood 1997; 89:2951-8.
14. Jury EC, Kabouridis PS. T-lymphocyte signalling in systemic lupus erythematosus: a lipid raft perspective. Lupus 2004; 13:413-22.
15. Nam KO, Kang H, Shin SM et al. Cross-linking of 4-1BB activates TCR-signaling pathways in CD8+ T lymphocytes. J Immunol 2005; 174:1898-905.
16. Putterman C. New approaches to the renal pathogenicity of anti-DNA antibodies in systemic lupus erythematosus. Autoimmun Rev 2004; 3:7-11.
17. Zhao Z, Weinstein E, Tuzova M et al. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential. Arthritis Rheum 2005; 52:522-30.
18. Lathrop SK, Huddleston CA, Dullforce PA et al. A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions. J Immunol 2004; 172:6735-43.
19. Grammer AC, Slota R, Fischer R et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003; 112: 1506-20.
20. Toubi E, Shoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 2004; 37:457-64.